Does DSIP Actually Work? An Honest Evidence Review

Research-use-only. TitrateLab is an independent peptide-data watchdog. We do not sell DSIP, we are not a clinic, and nothing here is medical advice or a dosing protocol. This is an evidence review.

The one-paragraph honest answer

DSIP is a nine-amino-acid peptide isolated from rabbit blood in 1977 and sold today as a subcutaneous “sleep injection.” The human evidence behind that pitch is thin, old, and small: essentially all of it comes from a handful of intravenous studies run between 1981 and 1992, none with more than 16 subjects, and none replicated by an independent modern team. The single best-controlled human sleep trial (Bes et al., 1992, double-blind, n=16) found the effects “weak” and concluded short-term DSIP is “not likely to be of major therapeutic benefit.” Forty-nine years after discovery, no DSIP gene, precursor protein, or receptor has ever been identified, and the most authoritative review is literally titled “a still unresolved riddle.” There are no modern, adequately-powered randomized controlled trials. DSIP is biologically interesting and apparently low-toxicity in the tiny old datasets, but it has never been properly tested in humans by modern standards, and it is not approved for anything.

Key facts

• What it is: a nonapeptide, sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), molecular weight ~848-850 Da.
• Discovered: 1977, by the Schoenenberger-Monnier group in Basel, from the cerebral venous blood of rabbits given low-frequency thalamic stimulation (Schoenenberger & Monnier, PNAS 1977; PMID 265572) — 49 years ago, with no receptor or gene found since.
• Named for: a delta-wave EEG effect in rabbits — not a demonstrated hypnotic effect in humans.
• Largest human sleep cohorts: n=6 to n=16. Zero modern RCTs.
• Best-controlled human sleep trial: Bes et al., 1992, n=16, double-blind — effects “weak,” “not likely to be of major therapeutic benefit” (PMID 1299794).
• Plasma half-life: roughly 7-8 minutes (rapidly cleared by aminopeptidases). A separate in-vitro brain-extract figure of ~15 minutes is sometimes quoted; do not conflate the two.
• Receptor / gene: none identified, ever (Kovalzon & Strekalova, J Neurochem 2006; PMID 16539679).
• Regulatory status (June 2026): not FDA-approved for anything. Removed from the FDA’s 503A Category 2 list in April 2026 (which is not an approval) and scheduled for a Pharmacy Compounding Advisory Committee review on July 24, 2026.
• Evidence grade: PRELIMINARY/LOW for sleep; LOW to VERY LOW for everything else.

What DSIP is

The 1977 discovery

DSIP’s entire origin is one experiment. In 1977, Marcel Monnier, Guido Schoenenberger, and colleagues in Basel electrically stimulated the intralaminar thalamic nuclei of rabbits at a low, “hypnogenic” frequency, drew the cerebral venous blood of those sleeping animals, and infused a dialysate of it into awake recipient rabbits. The recipients showed increased delta and spindle EEG activity — the electrical signature of slow-wave sleep. The active fraction was purified, sequenced, and synthesized (Schoenenberger & Monnier, “Characterization of a delta-electroencephalogram (-sleep)-inducing peptide,” PNAS 1977;74:1282-6, PMID 265572; the synthetic nonapeptide’s sequence and synthesis are detailed in the companion “XI” paper, Schoenenberger et al., Pflügers Arch 1978, PMID 568769).

Two things about that origin story matter, and the marketing omits both. First, the active material was delivered as an intravenous dialysate in rabbits — nothing like the way it is now sold or about a measured benefit in people. Second, the peptide was named for an EEG pattern in an animal, not for a measured sleep benefit in humans. Every downstream claim inherits that naming-versus-evidence gap.

The sequence

DSIP is the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, abbreviated WAGGDASGE, with a molecular weight around 848-850 Da. It is a small, charged, water-loving molecule — a fact that becomes important when we get to the blood-brain barrier. The isolation and sequence determination was done once, in 1977, and has never been re-verified by modern proteomic methods (Kovalzon & Strekalova, J Neurochem 2006).

The mechanism problem nobody resolved

This is the section the seller pages skip. It is also the most important section.

A substance with no known gene and no known receptor cannot have a well-characterized mechanism, no matter what a product page asserts.

No receptor, no gene — the “unresolved riddle”

The definitive skeptical synthesis of DSIP is Kovalzon & Strekalova’s 2006 review in the Journal of Neurochemistry, titled — with no hedging — “Delta sleep-inducing peptide (DSIP): a still unresolved riddle” (PMID 16539679). Its central point is brutal and still unchallenged: nobody has found

• a DSIP precursor protein,
• a precursor gene,
• a specific DSIP receptor,
• a receptor gene, or
• proof that the WAGGDASGE sequence is what actually circulates as “DSIP-like immunoreactivity” in tissue.

In plain language: for nearly half a century, nobody has established where DSIP is made, what it binds to, or even that the named peptide is genuinely the endogenous substance the antibodies are detecting. “DSIP-like immunoreactivity” reported in human cerebrospinal fluid or breast milk is an antibody cross-reactivity signal — it is not proof that the nonapeptide is a real, gene-encoded human hormone. A substance with no known gene and no known receptor cannot have a well-characterized mechanism, no matter what a product page asserts.

The ~7-8 minute half-life versus the “sleep-inducing” name

DSIP is metabolically fragile. In human and animal blood, the reported circulating half-life is on the order of 7-8 minutes (Pollard & Pomfrett, Eur J Anaesthesiol 2001), because aminopeptidases rapidly clip the N-terminal tryptophan off the molecule — degradation to tryptophan-equivalent products confirmed in vitro by Graf, Saegesser & Schoenenberger (Peptides 1987, PMID 3628078). A separate in-vitro figure — roughly 15 minutes in brain-extract homogenates — sometimes gets quoted as “the half-life.” These are two different measurements and should not be merged; either way, an injected dose is essentially gone from circulation within minutes.

Marketing claims durable, hours-long, even next-night "sleep" effects from a molecule that has left the bloodstream before most people finish brushing their teeth.

That creates a genuine pharmacological tension. Marketing claims durable, hours-long, even next-night “sleep” effects from a molecule that has left the bloodstream before most people finish brushing their teeth. The decades-old rescue hypotheses — that DSIP binds an unnamed carrier protein, or acts as a one-shot “trigger” for a sleep program rather than needing sustained levels — are plausible narratives, but neither has ever been pinned to a named binding protein or demonstrated mechanism. Treat them as hypotheses, not facts.

Blood-brain barrier penetration: claimed, but softer than advertised

This one cuts both ways, and honesty requires saying so. Older radiotracer work (Kastin, Banks and colleagues, late 1970s-1980s) reported that small amounts of radiolabeled DSIP cross the blood-brain barrier by a non-competitive mechanism — more brain uptake than blood contamination alone could explain — though a later study reported the opposite, a saturable carrier. So a charged nonapeptide can enter the brain to some degree, and the flat objection that “it can’t possibly reach the brain” is overstated.

But “detectable crossing” is not “pharmacologically meaningful brain concentration,” and a radiolabel tracks the label, not necessarily intact peptide. The most telling recent data point is indirect: in 2024, a Chinese group had to fuse DSIP to a separate BBB-crossing carrier peptide to improve its central effect in an insomnia mouse model, and the fusion construct outperformed plain DSIP (Mu et al., Front Pharmacol 2024; PMID 39444618). If native DSIP delivered itself to the brain efficiently, you would not need to bolt on a delivery vehicle. Treat the legacy claim that DSIP “freely crosses the BBB” as overstated.

The direct-to-brain test, and what it really showed

If DSIP were a true central sleep factor, placing it directly into the brain — bypassing the blood-brain barrier and the aminopeptidases entirely — should induce sleep cleanly. Obál and colleagues tried roughly that in 1986, injecting DSIP and several analogues directly into rat cerebral ventricles. Native DSIP did not increase sleep at all — but two degradation-resistant D-substituted analogues did promote sleep early in the night, and only a truncated fragment was promptly arousing (Obál et al., Pharmacol Biochem Behav 1986;24:889-894, PMID 3754970). The authors read the native-peptide null as confirmation that DSIP is destroyed too fast to act centrally — and that cuts both ways. It undercuts the idea that unmodified DSIP is a robust central sleep factor when delivered straight to the brain; but the fact that a stabilized version did promote sleep is the strongest mechanistic hint in the whole literature that a real effect may be waiting on better delivery. Promising and damning at once.

What the human trials actually found

The human evidence is small enough to walk through study by study.

The receipts — six studies that carry the entire DSIP story, quoted verbatim from the source papers. Read the result tags: the best-controlled human trial is weak-to-negative, the mechanism review calls it an unsolved riddle, and the one stress-axis test came back null.

The picture is the argument: the human sleep evidence is tiny (n=6–16), old, clustered in a single 1981–1992 window, and run mostly by the group that discovered the peptide. The one study run further afield and best-controlled — Bes 1992 (n=16, double-blind) — came back weak-to-negative. The only clearly positive sleep result in the last 30 years (Mu 2024) is in an animal model and required a separate carrier peptide bolted on to work.

The optimistic early reads (n=6, intravenous, one research group)

The supportive human data trace almost entirely to the originating Basel group around 1981-1984:

• Schneider-Helmert et al., 1981 — double-blind crossover, n=6 healthy volunteers, IV 25 nmol/kg in the morning. Reported subjective “sleep pressure,” ~59% more sleep within a ~130-minute window versus placebo, and delayed effects the following night. The authors reported no daytime sedation or other side effects (Int J Clin Pharmacol Ther Toxicol 1981;19:341-5, PMID 6895513).
• Schneider-Helmert & Schoenenberger, 1981 — n=6, IV, in subjects with disturbed sleep. Reported longer sleep duration with fewer interruptions and slightly more REM — but again the benefit appeared mainly in the second hour, with the first hour mildly arousing (Experientia 1981;37(9):913-7, PMID 7028502).

These are interesting and the “no daytime sedation, no obvious tolerance” signal is genuinely worth acknowledging. But they are tiny, intravenous (not the subcutaneous route hobbyists use), and run by the people who discovered the peptide — which is the maximum conflict-of-interest/optimism setup. They are hypothesis-generating, not proof.

The controlled double-blind that deflated it (n=16)

The best-controlled human sleep study is the one the sellers don’t quote. Bes, Hofman, Schuur & Van Boxtel (1992) ran a double-blind, placebo-controlled trial in 16 chronic insomniacs, with polysomnography and IV DSIP (25 nmol/kg). DSIP produced higher sleep efficiency and shorter sleep latency than placebo — but the authors stated plainly that the statistically significant effects were weak, that they were partly attributable to a change in the placebo group, that most measures were unimproved, and that short-term DSIP for chronic insomnia “is not likely to be of major therapeutic benefit” (Neuropsychobiology 1992;26(4):193-7, PMID 1299794).

This is the most honest data point in the entire sleep literature, and it is essentially negative. It is also still small (n=16) and short-term.

A note on the widely-cited “Monnier 1987” null: many secondary sources reference a Monnier-group 1987 double-blind study that found no significant sleep effect. We could not independently verify that primary record during research, so we do not cite it as a confirmed source. The directly-verifiable double-blind result that fails to support efficacy is the Bes 1992 trial (PMID 1299794) above.

Why six-to-sixteen-person 1980s IV studies can’t carry the claim

Three structural problems compound:

1. Power. With n=6-16, a real-but-modest effect and pure noise look similar, and a trial can easily flatter a compound by chance.
2. Route mismatch. Every supportive study used intravenous infusion. The grey market sells subcutaneous injection. No modern RCT has tested the route people actually use for the claim people actually want.
3. Independence. The positive data cluster in one research program. The one trial run further afield (Bes 1992) was the most negative. That is the opposite of the replication pattern you want to see before believing a drug works.

The non-sleep claims

DSIP is also marketed for stress, “calming the HPA axis,” pain, addiction withdrawal, thermoregulation, antioxidant effects, and even anti-aging. Here is where each claim actually stands.

Stress / HPA axis — the human data flatly contradict each other

The popular “DSIP lowers cortisol and calms your stress axis” claim is not reliably supported in humans. One controlled human endocrine study found that DSIP — even at large 3-4 mg IV infusions — had no effect on ACTH or cortisol secretion, whether CRH-stimulated or meal-induced (Späth-Schwalbe et al., Psychoneuroendocrinology 1995;20(3):231-7, PMID 7777652). Other reports (and rodent work) claim it does dampen the axis. When the human literature directly contradicts itself like this, the honest conclusion is “not established,” not “DSIP calms cortisol.”

Alcohol/opiate withdrawal — the largest human series, but open-label

The largest single human DSIP series is a withdrawal study: Dick, Grandjean & Tissot (1983) gave IV DSIP to 67 patients in alcohol or opiate withdrawal; of 49 evaluable patients, 48 showed a “beneficial effect” with rapid suppression of somatic withdrawal symptoms (Neuropsychobiology 1983;10(4):205-8, PMID 6328354). Those numbers sound dramatic, and this open-label signal is part of what underpins the FDA’s 2026 interest in DSIP for opioid withdrawal. But it was open-label, uncontrolled, unblinded, with no placebo arm, and ~27% of patients were excluded from the evaluable count. Withdrawal symptoms resolve with time and supportive care regardless. By any modern standard this is not efficacy evidence.

A related mechanistic correction worth making: DSIP is not a direct opioid-receptor agonist, despite the marketing — and despite the speculative framing in the 1983 paper’s own title. An in-vitro study found it did not bind any opioid-receptor subtype directly, but stimulated release of endogenous Met-enkephalin (Nakamura et al., Brain Res 1989;481:165-8). Any opioid-mediated effect would therefore be indirect.

Analgesia, thermoregulation, antioxidant, anti-tumor/longevity — animal or uncontrolled pilots

• Pain: one open pilot, small n, mixed pain types, no control (Larbig et al., Eur Neurol 1984;23:372-85). Hypothesis-generating only.
• Thermoregulation: rat work suggesting a serotonergic (5-HT1A) interaction (Tsunashima et al., Peptides 1994). No human data.
• Antioxidant: a series of 1990s Russian-language rat oxidative-stress studies reporting raised SOD/catalase/glutathione-peroxidase activity. All animal, mostly single-region literature, not independently replicated, and cited here as a class rather than from verified primary records.
• Anti-tumor / anti-aging: a longitudinal mouse study of “Deltaran” (a DSIP-containing preparation, not pure DSIP) reported no change in mean lifespan but increased maximum lifespan and reduced spontaneous tumor incidence (Popovich et al., Mech Ageing Dev 2003;124:721-7). Single Russian lab, animal, not replicated, and not pure DSIP.

None of this supports a human efficacy claim. It is the scattered, low-powered, mostly-rodent foundation of a marketing story far larger than itself.

DSIP vs the alternatives

DSIP vs melatonin

This comparison clarifies the evidence gap better than any single study. Melatonin has been tested in thousands of human subjects across numerous randomized controlled trials and meta-analyses; its modest effects on sleep onset and circadian timing are real, reproducible, and well-characterized. DSIP has been tested in ~50 humans, ever, mostly intravenously, mostly by one group, in studies from the 1980s, with the best-controlled trial coming back weak-to-negative. They are not in the same evidence universe. If your goal is the best-supported over-the-counter sleep aid, that is not DSIP.

DSIP vs epitalon, selank, and other “research peptides”

The same caveat applies, only more so: these compounds share DSIP’s profile of small, old, often single-region human data and no modern Western RCTs. “Better evidence than DSIP” is a low bar, and clearing it is not the same as being proven.

Side effects and what we don’t know

The genuinely reassuring part of the DSIP literature is its safety signal within the tiny old datasets: across decades of small studies, no serious adverse effects were reported — only transient headache, nausea, and vertigo — and an LD50 was reportedly never established, implying low acute toxicity (Pollard & Pomfrett, Eur J Anaesthesiol 2001).

That sentence needs three asterisks, though.

1. “No harm seen in tiny old studies” is not a modern safety clearance. There is no long-term human safety data and no modern toxicology. The FDA has indicated it identified no safety information for DSIP and has flagged a possible immunogenicity risk (the immune system reacting to the peptide) in compounded preparations.
2. The bigger near-term hazard is the vial, not the molecule. Grey-market research-chemical peptides are frequently underdosed, mislabeled, or the wrong compound entirely; independent testing programs have reported large fractions of samples missing their stated purity, plus occasional bacterial endotoxin above FDA limits and heavy-metal contamination. Critically, an HPLC purity certificate does not certify sterility or endotoxin. Anyone injecting an unregulated subcutaneous product is taking on a contamination/sterility risk that has nothing to do with whether DSIP “works.” (This is exactly the kind of batch-level purity problem TitrateLab tracks in our COA data.)
3. No long-term anything. No long-term efficacy, no long-term safety, no modern dose-response. The early animal work even showed bell-shaped dose-response curves — meaning “more is not more” — which further undermines any folk dosing rationale.

Regulatory status (as of June 2026 — this is a moving target)

DSIP is not FDA-approved for any indication. It sits in the research-chemical / “for research use only, not for human consumption” grey zone.

In April 2026, the FDA removed DSIP — referred to as emideltide — from 503A Category 2 (“significant safety risks”). That is not an approval, and the agency has been explicit that removal from Category 2 does not on its own authorize compounding. It moves the compound into a review process. DSIP/emideltide is scheduled for a Pharmacy Compounding Advisory Committee (PCAC) review on July 24, 2026 (part of a two-day PCAC session on July 23-24), where the committee will weigh the bulk substance — with opioid withdrawal, chronic insomnia, and narcolepsy named as the uses under evaluation. The outcome is unknown at the time of writing. Do not read “removed from Category 2” as “approved,” and do not read it as “banned” — it is neither. If you are reading this after late July 2026, check the PCAC outcome before relying on anything in this paragraph.

What doses appear in the research literature (and why that is not a protocol)

TitrateLab does not publish a DSIP dosing protocol — doing so would contradict our research-use-only mandate, and the honest reason is that no validated human protocol exists. For completeness, and so you can read the literature critically:

• The supportive studies used intravenous DSIP at 25 nmol/kg (Schneider-Helmert 1981; Bes 1992).
• Self-reported grey-market community practice clusters around ~100-300 mcg subcutaneously, once daily, 30-60 minutes before bed, in 8-12 week “cycles.”

Those are two different things. The community subcutaneous practice was never the route, dose, or delivery the studies validated, and the studies it borrows credibility from were weak-to-negative anyway. We report the community numbers as observed behavior, not as a recommendation, and explicitly not as medical advice.

Who DSIP might genuinely interest — and who should skip it

It may legitimately interest (as research/curiosity, not as a treatment):

• Sleep-optimization biohackers who have already exhausted sleep hygiene, light management, and melatonin, and want a straight evidence read on the next tier before deciding anything.
• Peptide-curious readers who want the real picture — including the one genuinely interesting early signal (sleep modulation with no obvious tolerance or rebound) — rather than a sales page.

It is not for, and should be skipped by:

• Anyone with diagnosed insomnia or a sleep disorder seeking treatment. You need a clinician and evidence-based options (CBT-I, evaluated medications) — not a peptide with one weak controlled trial.
• Anyone expecting melatonin-grade or drug-grade evidence. It does not exist.
• Anyone unwilling to accept grey-market sourcing risk and zero long-term safety data.
• Anyone pregnant, nursing, or on CNS-active medications.

The potential — stated honestly

There is a real but weak signal here, and it would be dishonest to call DSIP pure snake oil. A biologically real (or at least biologically active) molecule, a coherent stress/sleep rationale, a few small old studies hinting at sleep modulation without tolerance, and an apparently benign acute-safety profile add up to “interesting.” The blood-brain-barrier-fusion work even suggests there may be a genuine neuromodulatory effect that simply hasn’t been delivered or characterized properly.

But “interesting” is the ceiling, not the floor. The same molecule has no identified receptor, no identified gene, an awkward minutes-long half-life, a contested route to the brain, flatly contradictory human stress data, a best-controlled sleep trial that came back weak-to-negative, and a direct-to-brain rat study where it failed to induce sleep. Promising enough to study. Nowhere near proven enough to rely on.

Promising enough to study. Nowhere near proven enough to rely on.

The bottom line

DSIP is a 1977 rabbit-blood nonapeptide with a marketing story far larger than its evidence. The core “sleep-inducing” claim rests on tiny, old, intravenous studies from one research group; is contradicted by the best-controlled human trial; and is undercut by three hard facts — a ~7-8 minute half-life, a direct-to-brain rat study where it failed to induce sleep, and the fact that nobody has ever found its gene or receptor. Every non-sleep claim is weaker still. Acute safety looks reassuring in the small old data but is not a modern clearance, and grey-market product quality is its own separate, real risk. If you take one thing from this review: DSIP is biologically intriguing and has never been properly tested in humans by modern standards. Treat any stronger claim — from a vendor or anyone else — as marketing that has outrun its data.

Research-use-only. Not medical advice. Not a dosing protocol. Not an endorsement. TitrateLab does not sell DSIP.

References

1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA 1977;74(3):1282-1286. PMID 265572.
2. Schoenenberger GA, et al. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflügers Arch 1978;376(2):119-129. PMID 568769.
3. Schneider-Helmert D, Gnirss F, Monnier M, et al. Acute and delayed effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol 1981;19(8):341-345. PMID 6895513.
4. Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP on disturbed human sleep. Experientia 1981;37(9):913-917. PMID 7028502.
5. Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992;26(4):193-197. PMID 1299794.
6. Obál F Jr, et al. Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep. Pharmacol Biochem Behav 1986;24(4):889-894. PMID 3754970.
7. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem 2006;97(2):303-309. PMID 16539679.
8. Pollard BJ, Pomfrett CJD. Delta sleep-inducing peptide. Eur J Anaesthesiol 2001;18(7):419-422. PMID 11437870. (Editorial.)
9. Graf MV, Saegesser B, Schoenenberger GA. Degradation and aggregation of delta sleep-inducing peptide and two analogs in plasma and serum. Peptides 1987;8(4):599-603. PMID 3628078.
10. Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology 1983;10(4):205-208. PMID 6328354.
11. Nakamura A, et al. Delta-sleep-inducing peptide stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro. Brain Res 1989;481(1):165-168. PMID 2706459.
12. Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide in patients with chronic, pronounced pain episodes. Eur Neurol 1984;23(5):372-385. PMID 6548970.
13. Tsunashima K, et al. The effect of delta sleep-inducing peptide on the changes of body (core) temperature induced by serotonergic agonists in rats. Peptides 1994;15(1):61-65. PMID 8015981.
14. Späth-Schwalbe E, Schäfer A, Uthgenannt D, Born J, Fehm HL. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology 1995;20(3):231-237. PMID 7777652.
15. Popovich IG, Voitenkov BO, Anisimov VN, et al. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev 2003;124(6):721-731. PMID 12782416.
16. Mu X, Qu L, Yin L, et al. Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Front Pharmacol 2024;15:1439536. PMID 39444618.
17. Kastin AJ, Nissen C, Schally AV, Coy DH. Additional evidence that small amounts of a peptide can cross the blood-brain barrier. Pharmacol Biochem Behav 1979;11(6):717-719. PMID 583452. (Non-competitive transport: Banks WA, Kastin AJ, Coy DH, Brain Res 1984;301(2):201-207, PMID 6547363; a later study reported a saturable carrier instead — Zlokovic BV, et al., Peptides 1989, PMID 2547200.)
18. U.S. Food and Drug Administration. 503A Bulk Drug Substances framework update (April 2026); Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (emideltide/DSIP reviewed July 24, 2026).